These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 34726488)
21. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study. La Bella G; Lopizzo T; Lupo L; Angarano R; Curci A; Manti B; La Salandra G; Mosca A; De Nittis R; Arena F J Glob Antimicrob Resist; 2022 Dec; 31():236-238. PubMed ID: 36208851 [TBL] [Abstract][Full Text] [Related]
22. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort. Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J; Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116 [TBL] [Abstract][Full Text] [Related]
24. Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against Bovo F; Lombardo D; Lazzarotto T; Ambretti S; Gaibani P Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421265 [TBL] [Abstract][Full Text] [Related]
25. In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates. Findlay J; Poirel L; Nordmann P J Glob Antimicrob Resist; 2023 Mar; 32():66-71. PubMed ID: 36649860 [TBL] [Abstract][Full Text] [Related]
26. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study. Wei J; Zou C; Wang D; Huang A; Niu S J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260 [TBL] [Abstract][Full Text] [Related]
27. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201 [TBL] [Abstract][Full Text] [Related]
28. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354 [TBL] [Abstract][Full Text] [Related]
30. Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers. Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910899 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802 [TBL] [Abstract][Full Text] [Related]
32. In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Zou C; Wei J; Shan B; Chen X; Wang D; Niu S Infect Drug Resist; 2020; 13():3563-3568. PubMed ID: 33116675 [TBL] [Abstract][Full Text] [Related]
33. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Sun S; Chen K; Kong X; Tian W; Niu S Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161 [TBL] [Abstract][Full Text] [Related]
37. Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in Venditti C; Nisii C; D'Arezzo S; Vulcano A; Capone A; Antonini M; Ippolito G; Di Caro A Infect Drug Resist; 2019; 12():1935-1940. PubMed ID: 31308713 [No Abstract] [Full Text] [Related]
38. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014 [TBL] [Abstract][Full Text] [Related]